Basic and clinical aspects of BOTOX®

Mitchell F. Brin

doi:10.1016/j.toxicon.2009.03.021

Basic and clinical aspects of BOTOX^®

Mitchell F. Brin

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

BOTOX^® is a botulinum toxin type A product from Allergan that is approved in more than 70 countries, where it addresses unmet patient needs across a variety of indications. BOTOX^® is a well-characterized and highly purified biological product that is not interchangeable with any other botulinum neurotoxin. The pharmacology, efficacy and safety profile of BOTOX^® has been established in numerous preclinical and clinical studies in addition to meta-analyses. BOTOX^® exhibits a predictable response, with a concomitant low rate of neutralizing antibody formation. Allergan is committed to the development of new indications and novel biologics that are designed to benefit individuals with unmet medical needs.

Original language	English
Pages (from-to)	676-682
Number of pages	7
Journal	Toxicon
Volume	54
Issue number	5
DOIs	https://doi.org/10.1016/j.toxicon.2009.03.021
State	Published - Oct 2009
Externally published	Yes

Keywords

BOTOX
Botulinum
Botulinum neurotoxin complex
Dysphagia
Neutralizing antibodies
SNAP-25

Access to Document

10.1016/j.toxicon.2009.03.021

Cite this

@article{41f2e792eba440a9a0dff868de7e9f6c,

title = "Basic and clinical aspects of BOTOX{\textregistered}",

abstract = "BOTOX{\textregistered} is a botulinum toxin type A product from Allergan that is approved in more than 70 countries, where it addresses unmet patient needs across a variety of indications. BOTOX{\textregistered} is a well-characterized and highly purified biological product that is not interchangeable with any other botulinum neurotoxin. The pharmacology, efficacy and safety profile of BOTOX{\textregistered} has been established in numerous preclinical and clinical studies in addition to meta-analyses. BOTOX{\textregistered} exhibits a predictable response, with a concomitant low rate of neutralizing antibody formation. Allergan is committed to the development of new indications and novel biologics that are designed to benefit individuals with unmet medical needs.",

keywords = "BOTOX, Botulinum, Botulinum neurotoxin complex, Dysphagia, Neutralizing antibodies, SNAP-25",

author = "Brin, \{Mitchell F.\}",

year = "2009",

month = oct,

doi = "10.1016/j.toxicon.2009.03.021",

language = "English",

volume = "54",

pages = "676--682",

journal = "Toxicon",

issn = "0041-0101",

publisher = "Elsevier Ltd.",

number = "5",

}

TY - JOUR

T1 - Basic and clinical aspects of BOTOX®

AU - Brin, Mitchell F.

PY - 2009/10

Y1 - 2009/10

N2 - BOTOX® is a botulinum toxin type A product from Allergan that is approved in more than 70 countries, where it addresses unmet patient needs across a variety of indications. BOTOX® is a well-characterized and highly purified biological product that is not interchangeable with any other botulinum neurotoxin. The pharmacology, efficacy and safety profile of BOTOX® has been established in numerous preclinical and clinical studies in addition to meta-analyses. BOTOX® exhibits a predictable response, with a concomitant low rate of neutralizing antibody formation. Allergan is committed to the development of new indications and novel biologics that are designed to benefit individuals with unmet medical needs.

AB - BOTOX® is a botulinum toxin type A product from Allergan that is approved in more than 70 countries, where it addresses unmet patient needs across a variety of indications. BOTOX® is a well-characterized and highly purified biological product that is not interchangeable with any other botulinum neurotoxin. The pharmacology, efficacy and safety profile of BOTOX® has been established in numerous preclinical and clinical studies in addition to meta-analyses. BOTOX® exhibits a predictable response, with a concomitant low rate of neutralizing antibody formation. Allergan is committed to the development of new indications and novel biologics that are designed to benefit individuals with unmet medical needs.

KW - BOTOX

KW - Botulinum

KW - Botulinum neurotoxin complex

KW - Dysphagia

KW - Neutralizing antibodies

KW - SNAP-25

UR - https://www.scopus.com/pages/publications/68849104248

U2 - 10.1016/j.toxicon.2009.03.021

DO - 10.1016/j.toxicon.2009.03.021

M3 - Article

C2 - 19341758

AN - SCOPUS:68849104248

SN - 0041-0101

VL - 54

SP - 676

EP - 682

JO - Toxicon

JF - Toxicon

IS - 5